Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 6:53 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1321–1344 of 21,991 matching trials from the live ClinicalTrials.gov search.

Filters: Recruiting Clear all

Conditions: Trust
Interventions: Not listed
Lead sponsor: University of Central Florida; Other
Eligibility: 20 Years and older
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Mild Cognitive Impairment, Alzheimer Disease (AD), Dementia
Interventions: Not listed
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 700 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2031
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Hyperphosphatemia, Chronic Kidney Disease, Receiving Dialysis, ESRD (End-Stage Renal Disease), Dialysis
Interventions: AP301, AP301 Low Dose; Drug
Lead sponsor: Alebund Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 18
States / cities: Granada Hills, California • San Dimas, California • Lone Tree, Colorado + 14 more

Conditions: Neurofibromatosis 1
Interventions: Abemaciclib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hnscc, Head and Neck, Squamous Cell Cancer, Squamous Carcinoma, Squamous Cell Cancer of Head and Neck (SCCHN), Squamous Cell Carcinoma Head and Neck Cancer (HNSCC), Squamous Cell Carcinoma Mouth, Squamous Carcinoma Poorly Differentiated, Squamous Cell Cancer of the Head and Neck, Squamous Cell Carcinoma (SCC) of the Oral Cavity, Squamous Cell Carcinoma (SCC)
Interventions: Nivo800, Nivolumab; Drug
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Atherosclerosis, Stress, Inflammation
Interventions: Stress Reduction; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 45 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Mild Traumatic Brain Injury (mTBI), Concussion, Mild Traumatic Brain Injury
Interventions: Motor Activation Physical Therapy for mTBI, Standard of Care Physical Therapy for mTBI; Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Portland, Oregon • Salt Lake City, Utah

Conditions: Postoperative Pain, Anxiety Postoperative, Opioid Use
Interventions: Virtual Realty using a Microsoft Hololens, Empatica HR wristband, and EEG, Essence Olfactory Necklace, Bedside Olfaction Device; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 2 Diabetes
Interventions: Joint Home-DM-BAT Intervention, Usual Care; Behavioral
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 50 Years to 120 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Type 1 Diabetes, Diabetic Kidney Disease, Cardiovascular Diseases, Endothelial Dysfunction, Insulin Sensitivity
Interventions: Metformin Hcl 1000Mg Tab, Aminohippurate Sodium 20 % Injection, Iohexol 300 Mg/mL Injectable Solution, Placebo; Drug
Lead sponsor: Kalie Tommerdahl; Other
Eligibility: 12 Years to 25 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Aurora, Colorado • Seattle, Washington

Conditions: Ketosis
Interventions: Ketone Supplement, Beverage Tolerability Questionnaire (BTQ) and satiety visual analogue scale, Blood Draw, Urine Analysis; Dietary Supplement · Behavioral · Biological + 1 more
Lead sponsor: Ohio State University; Other
Eligibility: 20 Years to 70 Years
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Novato, California • Columbus, Ohio

Conditions: Glycogen Storage Disease Type IV, Adult Polyglucosan Body Disease, GSD4, GSD IV, APBD
Interventions: No intervention; Other
Lead sponsor: Duke University; Other
Eligibility: 0 Years to 90 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2035
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Neurological Regression, Myoclonus, Cherry Red Spot, Brain Atrophy
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 1 Day to 100 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Ulcerative Colitis, Crohn's Disease
Interventions: Vedolizumab IV, No Intervention; Drug · Other
Lead sponsor: Takeda; Industry
Eligibility: 2 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2033
U.S. locations: 22
States / cities: Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 19 more

Conditions: High Blood Pressure
Interventions: CardioCare Quest; Behavioral
Lead sponsor: Northern Arizona University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Flagstaff, Arizona

Conditions: Schizophenia Disorder, Schizoaffective Disorder
Interventions: Mobile Intervention for Social Recovery in Serious Mental Illness (mSITE), Supportive Contact (SC); Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 65 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: San Diego, California

Conditions: Acute Lower Limb Arterial Occlusion
Interventions: Artix Thrombectomy System; Device
Lead sponsor: Inari Medical; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 23
States / cities: San Francisco, California • New Haven, Connecticut • Washington D.C., District of Columbia + 20 more

Conditions: Periodontitis, Diabetes Mellitus Type 2
Interventions: local antibiotic application of topical minocycline, Scaling and Root Planing; Drug · Procedure
Lead sponsor: Case Western Reserve University; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Post Bariatricsurgery, Hypoglycemia
Interventions: Exendin-(9-39), Atropine, GLP-1 and GIP; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 65 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2027
U.S. locations: 2
States / cities: San Antonio, Texas

Conditions: Acute Myeloid Leukemia (AML)
Interventions: Ziftomenib, Placebo, Venetoclax, Azacitidine (AZA), Daunorubicin, Cytarabine (Ara-C); Drug
Lead sponsor: Kura Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 44
States / cities: Gilbert, Arizona • Clovis, California • La Jolla, California + 37 more

Conditions: Atrial Fibrillation, Arrhythmias, Cardiac, Cardiovascular Diseases
Interventions: Physical Activity Intervention Using FitBit Wearable Device; Device
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Neurocognitive Disorders
Interventions: Observational study; Other
Lead sponsor: Baptist Health South Florida; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2032
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Atrial Fibrillation, Obesity
Interventions: Tirzepatide, Placebo; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Aortic Valve Stenosis
Interventions: Transcatheter Aortic Valve Replacement; Procedure
Lead sponsor: The Society of Thoracic Surgeons; Other
Eligibility: 18 Years and older
Enrollment: 16,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2035
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Search by objective public record fields.

UCF Deciding Brains

Microbiome in Aging of Gut and Brain

A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China

Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas

Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)

The Effect of Mindfulness on Vascular Inflammation in Stable Coronary Disease

Postural Motor Activation Deficits After mTBI; Translating Laboratory Findings to Clinical Care

Virtual Reality and Olfactory Stimuli Multimodal Intervention to Reduce Post-Operative Pain and Anxiety in Patients Undergoing Cardiothoracic Surgery

Joint Patient and Caregiver Intervention for Older African Americans With Type 2 Diabetes

MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes

Variations in Ketone Metabolism

GBE Deficiency (GSD IV and APBD) Natural History Study

Natural History of Glycosphingolipid Storage Disorders and Glycoprotein Disorders

A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

CardioCare Quest: A Co-created Game for Improving Hypertension Treatment Compliance in Arizona

Context-Aware Mobile Intervention for Social Recovery in Serious Mental Illness (R33)

The ArtixASCEND Study

Effect of Arestin-Enhanced SRP on Periodontal and Glycemic Outcomes in Diabetics

Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Exercise Activity Intervention With Sensor-Based Engagement in Patients With Atrial Fibrillation

Integration of Neurocognitive Biomarkers Into a Neuro-Oncology Clinic

TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation

STS/ACC Transcatheter Valve Therapy Registry (TVT Registry)